帕诺比诺斯塔特的药理动力学:代谢稳定的物种间差异
Wenqiu Zhang1, Ju-Hee Oh2, Wenjuan Zhang2
1Departments of Pharmaceutics, Brain Barriers Research Center (Wenq. Zhang, J.-H.O., Wenj. Zhang, W.F.E.) and Medicinal Chemistry (C.C.A.), University of Minnesota, Minneapolis, Minnesota; and Department of Neurologic Surgery, UMass Chan Medical School, Worcester, Massachusetts (R.W.S.) elmqu011@umn.edu zhan4937@umn.edu.
胰岛素胺,一种基因素脱乙酶抑制剂,在小鼠菌株中显示出不同的体外稳定性,但在体内药理动力学和中枢神经系统输送方面相似,突出了预测药物行为的挑战.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 基斯脱乙酶 (HDAC) 抑制剂,如帕诺宾诺斯塔特,正在研究用于癌症治疗.
- 系统性使用后,Panobinostat在中枢神经系统 (CNS) 瘤中的疗效仍在争论中.
- 跨模型的panobinostat行为的变化需要了解其药理动力学和中枢神经系统分布.
研究的目的:
- 在各种生物矩阵中研究泛比诺斯塔的体外代谢稳定性.
- 评估体外稳定性如何影响panobinostat的体内药理动力学和中枢神经系统输送.
- 为了探索泛比诺斯塔的新陈代谢特征的跨菌株和跨物种差异.
主要方法:
- 在不同的小鼠血矩阵中,在不同的温度下对panobinostat进行了体外降解试验.
- 在体内对三种不同的小鼠菌株进行了泛尼斯塔的药理动力学研究.
- 在全身循环和中枢神经系统中评估泛比诺斯塔度.
主要成果:
- 泛比诺斯塔特在小鼠母体中呈现出快速的体外降解,在37°C加速,表明酶代谢.
- 实验室血稳定性在老鼠菌株和物种之间有显著的差异,但在人体血中,泛比诺斯塔是稳定的.
- 尽管体外有差异,但panobinostat在不同小鼠模型中表现出类似的体内系统性药物动力学行为.
结论:
- 在体外血稳定性的跨菌株差异并没有转化为小鼠中巴诺比诺斯塔特在体内药理学行为的差异或中枢神经系统的分布.
- 在体外代谢稳定性和体内处置性之间缺乏相关性表明,有复杂的因素影响了panobinostat的行为.
- 这种脱节可能会使巴诺比诺斯塔特和类似药物的药物开发工作复杂化.
更多相关视频
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Analysis of Population Pharmacokinetic Data
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Nonlinear Pharmacokinetics: Causes of Nonlinearity
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
